Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson’s Disease

Impaired mitophagy is one of the hallmarks of the pathogenesis of Parkinson’s disease, which highlights the importance of the proper functioning of mitochondria, as well as the processes of mitochondrial dynamics for the functioning of dopaminergic neurons. At the same time, the main factors leading...

Descripción completa

Detalles Bibliográficos
Autores principales: Blagov, Alexander V., Goncharov, Andrey G., Babich, Olga O., Larina, Viktoriya V., Orekhov, Alexander N., Melnichenko, Alexandra A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696222/
https://www.ncbi.nlm.nih.gov/pubmed/36432705
http://dx.doi.org/10.3390/pharmaceutics14112514
_version_ 1784838255136473088
author Blagov, Alexander V.
Goncharov, Andrey G.
Babich, Olga O.
Larina, Viktoriya V.
Orekhov, Alexander N.
Melnichenko, Alexandra A.
author_facet Blagov, Alexander V.
Goncharov, Andrey G.
Babich, Olga O.
Larina, Viktoriya V.
Orekhov, Alexander N.
Melnichenko, Alexandra A.
author_sort Blagov, Alexander V.
collection PubMed
description Impaired mitophagy is one of the hallmarks of the pathogenesis of Parkinson’s disease, which highlights the importance of the proper functioning of mitochondria, as well as the processes of mitochondrial dynamics for the functioning of dopaminergic neurons. At the same time, the main factors leading to disruption of mitophagy in Parkinson’s disease are mutations in the Pink1 and Parkin enzymes. Based on the characterized mutant forms, the marked cellular localization, and the level of expression in neurons, these proteins can be considered promising targets for the development of drugs for Parkinson’s therapy. This review will consider such class of drug compounds as mitophagy activators and these drugs in the treatment of Parkinson’s disease.
format Online
Article
Text
id pubmed-9696222
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96962222022-11-26 Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson’s Disease Blagov, Alexander V. Goncharov, Andrey G. Babich, Olga O. Larina, Viktoriya V. Orekhov, Alexander N. Melnichenko, Alexandra A. Pharmaceutics Review Impaired mitophagy is one of the hallmarks of the pathogenesis of Parkinson’s disease, which highlights the importance of the proper functioning of mitochondria, as well as the processes of mitochondrial dynamics for the functioning of dopaminergic neurons. At the same time, the main factors leading to disruption of mitophagy in Parkinson’s disease are mutations in the Pink1 and Parkin enzymes. Based on the characterized mutant forms, the marked cellular localization, and the level of expression in neurons, these proteins can be considered promising targets for the development of drugs for Parkinson’s therapy. This review will consider such class of drug compounds as mitophagy activators and these drugs in the treatment of Parkinson’s disease. MDPI 2022-11-19 /pmc/articles/PMC9696222/ /pubmed/36432705 http://dx.doi.org/10.3390/pharmaceutics14112514 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Blagov, Alexander V.
Goncharov, Andrey G.
Babich, Olga O.
Larina, Viktoriya V.
Orekhov, Alexander N.
Melnichenko, Alexandra A.
Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson’s Disease
title Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson’s Disease
title_full Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson’s Disease
title_fullStr Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson’s Disease
title_full_unstemmed Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson’s Disease
title_short Prospects for the Development of Pink1 and Parkin Activators for the Treatment of Parkinson’s Disease
title_sort prospects for the development of pink1 and parkin activators for the treatment of parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696222/
https://www.ncbi.nlm.nih.gov/pubmed/36432705
http://dx.doi.org/10.3390/pharmaceutics14112514
work_keys_str_mv AT blagovalexanderv prospectsforthedevelopmentofpink1andparkinactivatorsforthetreatmentofparkinsonsdisease
AT goncharovandreyg prospectsforthedevelopmentofpink1andparkinactivatorsforthetreatmentofparkinsonsdisease
AT babicholgao prospectsforthedevelopmentofpink1andparkinactivatorsforthetreatmentofparkinsonsdisease
AT larinaviktoriyav prospectsforthedevelopmentofpink1andparkinactivatorsforthetreatmentofparkinsonsdisease
AT orekhovalexandern prospectsforthedevelopmentofpink1andparkinactivatorsforthetreatmentofparkinsonsdisease
AT melnichenkoalexandraa prospectsforthedevelopmentofpink1andparkinactivatorsforthetreatmentofparkinsonsdisease

Ejemplares similares